Replies to post #71302 on Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

That's how I remember it, too. The thing is that there aren't many treatment options available for advanced cervical cancer.

I personally feel that the GOG study results demonstrate clearly enough that there is something going on with Axal, and I do not feel that pembro has demonstrated anything that much stronger, except for three advantages:

1) Demonstrable responses that are long lived. ADXS does not have responses for the most part

2) A biomarker. This makes a big difference in what the FDA is willing to do

3) Long, extremely deep experience with pembro. This raises a lot of the comfort levels for the regulators.